# A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer

> **NCT00510718** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 140 (actual)

## Conditions studied

- Prostate Cancer
- Hormone Refractory Prostate Cancer

## Interventions

- **DRUG:** MDV3100

## Key facts

- **NCT ID:** NCT00510718
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07-23
- **Primary completion:** 2008-12-08
- **Final completion:** 2018-04-02
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2019-10-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00510718

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00510718, "A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00510718. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*